Compare Gilead Sciences, Inc. (GILD) vs Rivian Automotive, Inc. (RIVN) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

Rivian stock trades at $16.91, down 3.37% on the day, as the EV maker continues its transition toward profitability. Recent earnings beats and the upcoming R2 vehicle launch provide optimism, though negative cash flow and substantial losses remain concerns. Technical indicators show a bullish trend with support at $16 and resistance at $18-19, while analyst consensus favors a buy rating with a $19.22 price target.

The investment case hinges on Rivian's ability to scale production and achieve profitability, with the R2 launch representing a potential inflection point. Key risks include ongoing cash burn, competitive pressures, and execution challenges in a capital-intensive industry. Upside potential exists if the company can demonstrate sustainable margin improvement and demand strength for new models.